
TVRD Stock Forecast & Price Target
TVRD Analyst Ratings
Bulls say
Tvardi Therapeutics is attractive fundamentally because its STAT3 franchise has already shown direct human target engagement, with TTI-101 producing an 18% confirmed partial response rate, 53% disease control, and 100% pY-STAT3 reduction in biopsied HCC patients, while the company’s clean safety profile and no dose-limiting toxicities support continued development. The investment case is further strengthened by TTI-109, which delivered equivalent active-moiety exposure, dose-proportional PK, profound immune-cell reductions, and markedly shorter diarrhea duration than TTI-101, suggesting the tolerability issue is being solved without sacrificing pharmacology. Financially, the company held $25 million in cash and short-term investments as of March 31, 2026, with operations funded into 4Q26, while the market capitalization of about $29 million implies near-zero value for the pipeline despite multiple catalysts.
Bears say
Tvardi Therapeutics is fundamentally challenged by a target class that has repeatedly failed in the clinic: direct STAT3 inhibition has faced structural drug-design barriers, poor selectivity, off-target toxicity, and no FDA-approved precedent despite more than two decades of effort. Its latest setback in the Phase 2 REVERT IPF trial, where roughly 88 patients were treated and discontinuation rates reached 56.7% and 62.1% in the TTI-101 arms versus 10.3% for placebo, reinforced tolerability concerns while the unusually shallow placebo decline made efficacy harder to prove. With no approved products, dependence on TTI-101 in HCC and TTI-109, and only $25 million in cash as of March 31, 2026, the company also faces meaningful development, regulatory, and dilution risk.
This aggregate rating is based on analysts' research of Tvardi Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TVRD Analyst Forecast & Price Prediction
Start investing in TVRD
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Tvardi Therapeutics Inc (TVRD) Forecast
TVRD Analyst Forecast & Price Prediction
Start investing in TVRD
Order type
Buy in
Order amount
Est. shares
0 shares